المؤلفون: Liu, X, Munro, APS, Wright, A, Feng, S, Janani, L, Aley, PK, Babbage, G, Baker, J, Baxter, D, Bawa, T, Bula, M, Cathie, K, Chatterjee, K, Dodd, K, Enever, Y, Fox, L, Qureshi, E, Goodman, AL, Green, CA, Haughney, J, Hicks, A, Jones, CE, Kanji, N, van der Klaauw, AA, Libri, V, Llewelyn, MJ, Mansfield, R, Maallah, M, McGregor, AC, Minassian, AM, Moore, P, Mughal, M, Mujadidi, YF, Belhadef, HT, Holliday, K, Osanlou, O, Osanlou, R, Owens, DR, Pacurar, M, Palfreeman, A, Pan, D, Rampling, T, Regan, K, Saich, S, Saralaya, D, Sharma, S, Sheridan, R, Stokes, M, Thomson, EC, Todd, S, Lambe, T, Snape, MD

المساهمون: group, COV-BOOST study

Relation: https://ora.ox.ac.uk/objects/uuid:41b94e40-b1aa-414e-96e2-61e846cd5112; https://doi.org/10.1016/j.jinf.2023.04.012

الاتاحة: https://doi.org/10.1016/j.jinf.2023.04.012
https://ora.ox.ac.uk/objects/uuid:41b94e40-b1aa-414e-96e2-61e846cd5112

المؤلفون: Liu, X, Munro, APS, Wright, A, Feng, S, Janani, L, Aley, PK, Babbage, G, Baker, J, Baxter, D, Bawa, T, Bula, M, Cathie, K, Chatterjee, K, Dodd, K, Enever, Y, Fox, L, Qureshi, E, Goodman, AL, Green, CA, Haughney, J, Hicks, A, Jones, CE, Kanji, N, van der Klaauw, AA, Libri, V, Llewelyn, MJ, Mansfield, R, Maallah, M, McGregor, AC, Minassian, AM, Moore, P, Mughal, M, Mujadidi, YF, Belhadef, HT, Holliday, K, Osanlou, O, Osanlou, R, Owens, DR, Pacurar, M, Palfreeman, A, Pan, D, Rampling, T, Regan, K, Saich, S, Saralaya, D, Sharma, S, Sheridan, R, Stokes, M, Thomson, EC, Todd, S, Twelves, C, Read, RC, Charlton, S, Hallis, B, Ramsay, M, Andrews, N, Lambe, T, Nguyen-Van-Tam, JS, Cornelius, V, Snape, MD, Faust, SN

المصدر: Journal of Infection , 87 (1) pp. 18-26. (2023)

مصطلحات موضوعية: Antibodies, Boosters, COVID-19, Immunisation, Immunogenicity, SARS-CoV-2, T-Cells, Vaccination

وصف الملف: application/pdf

Relation: https://discovery.ucl.ac.uk/id/eprint/10171907/1/1-s2.0-S0163445323002475-main.pdf; https://discovery.ucl.ac.uk/id/eprint/10171907/

الاتاحة: https://discovery.ucl.ac.uk/id/eprint/10171907/1/1-s2.0-S0163445323002475-main.pdf
https://discovery.ucl.ac.uk/id/eprint/10171907/

المؤلفون: Liu, X, Munro, APS, Wright, A, Feng, S, Janani, L, Aley, PK, Babbage, G, Baker, J, Baxter, D, Bawa, T, Bula, M, Cathie, K, Chatterjee, K, Dodd, K, Enever, Y, Fox, L, Qureshi, E, Goodman, AL, Green, CA, Haughney, J, Hicks, A, Jones, CE, Kanji, N, Van der Klaauw, AA, Libri, V, Llewelyn, MJ, Mansfield, R, Maallah, M, McGregor, AC, Minassian, AM, Moore, P, Mughal, M, Mujadidi, YF, Belhadef, HT, Holliday, K, Osanlou, O, Osanlou, R, Owens, DR, Pacurar, M, Palfreeman, A, Pan, D, Rampling, T, Regan, K, Saich, S, Saralaya, D, Sharma, S, Sheridan, R, Stokes, M, Thomson, EC, Todd, S, Twelves, C, Read, RC, Charlton, S, Hallis, B, Ramsay, M, Andrews, N, Lambe, T, Nguyen-Van-Tam, JS, Cornelius, V, Snape, MD, Faust, SN, COV-BOOST study group

المصدر: 26 ; 18

جغرافية الموضوع: England

Relation: Journal of Infection; http://hdl.handle.net/10044/1/103918

الاتاحة: http://hdl.handle.net/10044/1/103918
https://doi.org/10.1016/j.jinf.2023.04.012

المؤلفون: Munro, APS, Feng, S, Janani, L, Cornelius, V, Aley, PK, Babbage, G, Baxter, D, Bula, M, Cathie, K, Chatterjee, K, Dodd, K, Enever, Y, Qureshi, E, Goodman, AL, Green, CA, Harndahl, L, Haughney, J, Hicks, A, Van der Klaauw, AA, Kanji, N, Libri, V, Llewelyn, MJ, McGregor, AC, Maallah, M, Minassian, AM, Moore, P, Mughal, M, Mujadidi, YF, Holliday, K, Osanlou, O, Osanlou, R, Owens, DR, Pacurar, M, Palfreeman, A, Pan, D, Rampling, T, Regan, K, Saich, S, Bawa, T, Saralaya, D, Sharma, S, Sheridan, R, Thomson, EC, Todd, S, Twelves, C, Read, RC, Charlton, S, Hallis, B, Ramsay, M, Andrews, N, Lambe, T, Nguyen-Van-Tam, JS, Snape, MD, Liu, X, Faust, SN, COV-BOOST study group

المساهمون: National Institute for Health Research

المصدر: 1141 ; 1131

مصطلحات موضوعية: COV-BOOST study group, Microbiology, 1103 Clinical Sciences, 1108 Medical Microbiology, 1117 Public Health and Health Services

جغرافية الموضوع: United States

Relation: Lancet Infectious Diseases; http://hdl.handle.net/10044/1/98005; COV-BOOST

الاتاحة: http://hdl.handle.net/10044/1/98005
https://doi.org/10.1016/S1473-3099(22)00271-7

المؤلفون: Maallah, M., Needle, J. J., Alwan, N.

مصطلحات موضوعية: RA0421 Public health. Hygiene. Preventive Medicine, RC0254 Neoplasms. Tumors. Oncology (including Cancer)

وصف الملف: text

Relation: https://openaccess.city.ac.uk/id/eprint/28948/1/DOC-20221002-WA0027.pdf; Maallah, M., Needle, J. J. https://openaccess.city.ac.uk/view/creators_id/justin=2Eneedle=2E1.html orcid:0000-0003-0727-1391 orcid:0000-0003-0727-1391 Alwan, N. (2022). Barriers Impeding Early Detection of Breast Cancer in Iraq: A Critical Analysis. Azerbaijan Medical Journal, 62(07), pp. 2845-2863.

الاتاحة: https://openaccess.city.ac.uk/id/eprint/28948/
https://openaccess.city.ac.uk/id/eprint/28948/1/DOC-20221002-WA0027.pdf

المؤلفون: Munro, A. P. S., Feng, S., Janani, L., Cornelius, V., Aley, P. K., Babbage, G., Baxter, D., Bula, M., Cathie, K., Chatterjee, K., Dodd, K., Enever, Y., Qureshi, E., Goodman, A. L., Green, C. A., Harndahl, L., Haughney, J., Hicks, A., van der Klaauw, A. A., Kanji, N., Libri, V., Llewelyn, M. J., McGregor, A. C., Maallah, M., Minassian, A. M., Moore, P., Mughal, M., Mujadidi, Y. F., Holliday, K., Osanlou, O., Osanlou, R., Owens, D. R., Pacurar, M., Palfreeman, A., Pan, D., Rampling, T., Regan, K., Saich, S., Bawa, T., Saralaya, D., Sharma, S., Sheridan, R., Thomson, E. C., Todd, S., Twelves, C., Read, R. C., Charlton, S., Hallis, B., Ramsay, M., Andrews, N., Lambe, T., Nguyen-Van-Tam, J. S., Snape, M. D., Liu, X., Faust, S. N.

مصطلحات موضوعية: 2019-nCoV Vaccine mRNA-1273, Aged, Antibodies, Viral, BNT162 Vaccine, COVID-19/prevention & control, COVID-19 Vaccines/adverse effects, ChAdOx1 nCoV-19, Female, Humans, Immunogenicity, Vaccine, Immunoglobulin G, Male, Middle Aged, SARS-CoV-2

Relation: https://linkinghub.elsevier.com/retrieve/pii/S1473-3099(22)00271-7; Lancet Infect Dis. 2022 Aug;22(8):1131-1141. doi:10.1016/S1473-3099(22)00271-7. Epub 2022 May 9.; https://rde.dspace-express.com/handle/11287/622525; The Lancet Infectious diseases; PMC9084623 an investigator on studies funded or sponsored by vaccine manufacturers, including AstraZeneca, GlaxoSmithKline, Janssen, Medimmune, Merck, Pfizer, Sanofi, and Valneva, and receives no personal financial payment for this work. SNF acts on behalf of University Hospital Southampton NHS Foundation Trust as an investigator or consults on clinical trials and studies of COVID-19 vaccines and other vaccines funded or sponsored by vaccine manufacturers, including Janssen, Pfizer, AstraZeneca, GlaxoSmithKline, Novavax, Seqirus, Sanofi, Medimmune, Merck, and Valneva, and receives no personal financial payment for this work. ALG is named as an inventor on a patent covering the use of a particular promoter construct that is often used in ChAdOx1-vectored vaccines and is incorporated in the ChAdOx1 nCoV-19 vaccine and could benefit from royalty income paid to the University of Oxford from sales of this vaccine by AstraZeneca and its sublicensees under the university's revenue sharing policy. JH has received payments for presentations for AstraZeneca, Boehringer Ingelheim, Chiesi, and Cipla & Teva. VL acts on behalf of University College London Hospitals NHS Foundation Trust as an investigator on clinical trials of COVID-19 vaccines funded or sponsored by vaccine manufacturers, including Pfizer, AstraZeneca, and Valneva, and receives no personal financial payment for this work. PM acts on behalf of University Hospital Southampton NHS Foundation Trust and The Adam Practice as an investigator on studies funded or sponsored by vaccine manufacturers, including AstraZeneca, GlaxoSmithKline, Novavax, Medicago, and Sanofi, and receives no personal financial payment for this work. JSN-V-T was seconded to the Department of Health and Social Care, England, until March 31, 2022. MR has provided post-marketing surveillance reports on vaccines for Pfizer and GlaxoSmithKline, for which a cost recovery charge is made. MDS acts on behalf of the University of Oxford as an investigator on studies funded or sponsored by vaccine manufacturers, including AstraZeneca, GlaxoSmithKline, Pfizer, Novavax, Janssen, Medimmune, and MCM, and has received no personal financial payment for this work. All other authors declare no competing interests.

الاتاحة: https://doi.org/10.1016/s1473-3099(22)00271-7
https://rde.dspace-express.com/handle/11287/622525

المؤلفون: Munro, A. P. S., Feng, S., Janani, L., Cornelius, V., Aley, P. K., Babbage, G., Baxter, D., Bula, M., Cathie, K., Chatterjee, K., Dodd, K., Enever, Y., Qureshi, E., Goodman, A. L., Green, C. A., Harndahl, L., Haughney, J., Hicks, A., van der Klaauw, A. A., Kanji, N., Libri, V., Llewelyn, M. J., McGregor, A. C., Maallah, M., Minassian, A. M., Moore, P., Mughal, M., Mujadidi, Y. F., Holliday, K., Osanlou, O., Osanlou, R., Owens, D. R., Pacurar, M., Palfreeman, A., Pan, D., Rampling, T., Regan, K., Saich, S., Bawa, T., Saralaya, D., Sharma, S., Sheridan, R., Thomson, E. C., Todd, S., Twelves, C., Read, R. C., Charlton, S., Hallis, B., Ramsay, M., Andrews, N., Lambe, T., Nguyen-Van-Tam, J. S., Snape, M. D., Liu, X., Faust, S. N.

مصطلحات موضوعية: 2019-nCoV Vaccine mRNA-1273, Aged, Antibodies, Viral, BNT162 Vaccine, COVID-19/prevention & control, COVID-19 Vaccines/adverse effects, ChAdOx1 nCoV-19, Female, Humans, Immunogenicity, Vaccine, Immunoglobulin G, Male, Middle Aged, SARS-CoV-2

Relation: https://linkinghub.elsevier.com/retrieve/pii/S1473-3099(22)00271-7; Lancet Infect Dis. 2022 Aug;22(8):1131-1141. doi:10.1016/S1473-3099(22)00271-7. Epub 2022 May 9.; The Lancet Infectious diseases; PMC9084623 an investigator on studies funded or sponsored by vaccine manufacturers, including AstraZeneca, GlaxoSmithKline, Janssen, Medimmune, Merck, Pfizer, Sanofi, and Valneva, and receives no personal financial payment for this work. SNF acts on behalf of University Hospital Southampton NHS Foundation Trust as an investigator or consults on clinical trials and studies of COVID-19 vaccines and other vaccines funded or sponsored by vaccine manufacturers, including Janssen, Pfizer, AstraZeneca, GlaxoSmithKline, Novavax, Seqirus, Sanofi, Medimmune, Merck, and Valneva, and receives no personal financial payment for this work. ALG is named as an inventor on a patent covering the use of a particular promoter construct that is often used in ChAdOx1-vectored vaccines and is incorporated in the ChAdOx1 nCoV-19 vaccine and could benefit from royalty income paid to the University of Oxford from sales of this vaccine by AstraZeneca and its sublicensees under the university's revenue sharing policy. JH has received payments for presentations for AstraZeneca, Boehringer Ingelheim, Chiesi, and Cipla & Teva. VL acts on behalf of University College London Hospitals NHS Foundation Trust as an investigator on clinical trials of COVID-19 vaccines funded or sponsored by vaccine manufacturers, including Pfizer, AstraZeneca, and Valneva, and receives no personal financial payment for this work. PM acts on behalf of University Hospital Southampton NHS Foundation Trust and The Adam Practice as an investigator on studies funded or sponsored by vaccine manufacturers, including AstraZeneca, GlaxoSmithKline, Novavax, Medicago, and Sanofi, and receives no personal financial payment for this work. JSN-V-T was seconded to the Department of Health and Social Care, England, until March 31, 2022. MR has provided post-marketing surveillance reports on vaccines for Pfizer and GlaxoSmithKline, for which a cost recovery charge is made. MDS acts on behalf of the University of Oxford as an investigator on studies funded or sponsored by vaccine manufacturers, including AstraZeneca, GlaxoSmithKline, Pfizer, Novavax, Janssen, Medimmune, and MCM, and has received no personal financial payment for this work. All other authors declare no competing interests.; https://hdl.handle.net/11287/622525

الاتاحة: https://hdl.handle.net/11287/622525
https://doi.org/10.1016/s1473-3099(22)00271-7

المؤلفون: Liu, X., Munro, A. P. S., Wright, A., Feng, S., Janani, L., Aley, P. K., Babbage, G., Baker, J., Baxter, D., Bawa, T., Bula, M., Cathie, K., Chatterjee, K., Dodd, K., Enever, Y., Fox, L., Qureshi, E., Goodman, A. L., Green, C. A., Haughney, J., Hicks, A., Jones, C. E., Kanji, N., van der Klaauw, A. A., Libri, V., Llewelyn, M. J., Mansfield, R., Maallah, M., McGregor, A. C., Minassian, A. M., Moore, P., Mughal, M., Mujadidi, Y. F., Belhadef, H. T., Holliday, K., Osanlou, O., Osanlou, R., Owens, D. R., Pacurar, M., Palfreeman, A., Pan, D., Rampling, T., Regan, K., Saich, S., Saralaya, D., Sharma, S., Sheridan, R., Stokes, M., Thomson, E. C., Todd, S., Twelves, C., Read, R. C., Charlton, S., Hallis, B., Ramsay, M., Andrews, N., Lambe, T., Nguyen-Van-Tam, J. S., Cornelius, V., Snape, M. D., Faust, S. N.

مصطلحات موضوعية: Female, Humans, Aged, Male, COVID-19 Vaccines, BNT162 Vaccine, ChAdOx1 nCoV-19, COVID-19/prevention & control, SARS-CoV-2, Viral Vaccines, Immunity, United Kingdom, Immunoglobulin G, Antibodies, Viral, Vaccination, Immunogenicity, Vaccine, Boosters, Covid-19, Immunisation, T-Cells

Relation: https://linkinghub.elsevier.com/retrieve/pii/S0163-4453(23)00247-5; Liu X, Munro APS, Wright A, Feng S, Janani L, Aley PK, et al. Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK: eight-month analyses of the COV-BOOST trial. The Journal of infection. 2023;87(1):18-26.; The Journal of infection; PMC10116128; https://hdl.handle.net/11287/623011

الاتاحة: https://hdl.handle.net/11287/623011
https://doi.org/10.1016/j.jinf.2023.04.012

المؤلفون: Liu, X., Munro, A. P. S., Wright, A., Feng, S., Janani, L., Aley, P. K., Babbage, G., Baker, J., Baxter, D., Bawa, T., Bula, M., Cathie, K., Chatterjee, K., Dodd, K., Enever, Y., Fox, L., Qureshi, E., Goodman, A. L., Green, C. A., Haughney, J., Hicks, A., Jones, C. E., Kanji, N., van der Klaauw, A. A., Libri, V., Llewelyn, M. J., Mansfield, R., Maallah, M., McGregor, A. C., Minassian, A. M., Moore, P., Mughal, M., Mujadidi, Y. F., Belhadef, H. T., Holliday, K., Osanlou, O., Osanlou, R., Owens, D. R., Pacurar, M., Palfreeman, A., Pan, D., Rampling, T., Regan, K., Saich, S., Saralaya, D., Sharma, S., Sheridan, R., Stokes, M., Thomson, E. C., Todd, S., Twelves, C., Read, R. C., Charlton, S., Hallis, B., Ramsay, M., Andrews, N., Lambe, T., Nguyen-Van-Tam, J. S., Cornelius, V., Snape, M. D., Faust, S. N.

مصطلحات موضوعية: Female, Humans, Aged, Male, COVID-19 Vaccines, BNT162 Vaccine, ChAdOx1 nCoV-19, COVID-19/prevention & control, SARS-CoV-2, Viral Vaccines, Immunity, United Kingdom, Immunoglobulin G, Antibodies, Viral, Vaccination, Immunogenicity, Vaccine, Boosters, Covid-19, Immunisation, T-Cells

Relation: Liu X, Munro APS, Wright A, Feng S, Janani L, Aley PK, et al. Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK: eight-month analyses of the COV-BOOST trial. The Journal of infection. 2023;87(1):18-26.; The Journal of infection; PMC10116128; https://hdl.handle.net/11287/623011

الاتاحة: https://hdl.handle.net/11287/623011
https://doi.org/10.1016/j.jinf.2023.04.012

المؤلفون: Liu, X., Munro, A. P. S., Wright, A., Feng, S., Janani, L., Aley, P. K., Babbage, G., Baker, J., Baxter, D., Bawa, T., Bula, M., Cathie, K., Chatterjee, K., Dodd, K., Enever, Y., Fox, L., Qureshi, E., Goodman, A. L., Green, C. A., Haughney, J., Hicks, A., Jones, C. E., Kanji, N., van der Klaauw, A. A., Libri, V., Llewelyn, M. J., Mansfield, R., Maallah, M., McGregor, A. C., Minassian, A. M., Moore, P., Mughal, M., Mujadidi, Y. F., Belhadef, H. T., Holliday, K., Osanlou, O., Osanlou, R., Owens, D. R., Pacurar, M., Palfreeman, A., Pan, D., Rampling, T., Regan, K., Saich, S., Saralaya, D., Sharma, S., Sheridan, R., Stokes, M., Thomson, E. C., Todd, S., Twelves, C., Read, R. C., Charlton, S., Hallis, B., Ramsay, M., Andrews, N., Lambe, T., Nguyen-Van-Tam, J. S., Cornelius, V., Snape, M. D., Faust, S. N.

مصطلحات موضوعية: Female, Humans, Aged, Male, COVID-19 Vaccines, BNT162 Vaccine, ChAdOx1 nCoV-19, COVID-19/prevention & control, SARS-CoV-2, Viral Vaccines, Immunity, United Kingdom, Immunoglobulin G, Antibodies, Viral, Vaccination, Immunogenicity, Vaccine, Boosters, Covid-19, Immunisation, T-Cells

Relation: https://linkinghub.elsevier.com/retrieve/pii/S0163-4453(23)00247-5; Liu X, Munro APS, Wright A, Feng S, Janani L, Aley PK, et al. Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK: eight-month analyses of the COV-BOOST trial. The Journal of infection. 2023;87(1):18-26.; The Journal of infection; PMC10116128; https://hdl.handle.net/11287/623011

الاتاحة: https://hdl.handle.net/11287/623011
https://doi.org/10.1016/j.jinf.2023.04.012